Summary
Global Markets Direct’s, ‘Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Review, H1 2016’, provides in depth analysis on Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted pipeline therapeutics.
The report provides comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1)
- The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
AdAlta Pty Ltd.
Bristol-Myers Squibb Company
Epigen Biosciences, Inc.
F. Hoffmann-La Roche Ltd.
Ono Pharmaceutical Co., Ltd.
RxBio, Inc.
Sanofi
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) Overview 6
Therapeutics Development 7
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Products under Development by Stage of Development 7
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Products under Development by Therapy Area 8
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Products under Development by Indication 9
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Products under Development by Companies 12
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Companies Involved in Therapeutics Development 21
AdAlta Pty Ltd. 21
Bristol-Myers Squibb Company 22
Epigen Biosciences, Inc. 23
F. Hoffmann-La Roche Ltd. 24
Ono Pharmaceutical Co., Ltd. 25
RxBio, Inc. 26
Sanofi 27
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Drug Profiles 28
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
BMS-986020 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BMS-986202 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ITMN-10534 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Rx-100 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
SAR-100842 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Antagonize Lysophosphatidic Acid Receptor 1 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Dormant Projects 39
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Featured News & Press Releases 41
Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation 41
May 11, 2011: Amira To Present Preclinical Data On AM152 At Annual Meeting Of American Thoracic Society 41
May 02, 2011: Amira Pharmaceuticals Completes Phase I Clinical Study Of AM152 42
Apr 19, 2011: Amira Receives Orphan Drug Status For AM152 In Idiopathic Pulmonary Fibrosis 42
Oct 28, 2010: Amira Initiates Phase I Clinical Trial For AM152 42
Sep 27, 2010: Amira Submits AM152 IND To FDA For Potential Use In Fibrotic Diseases 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by AdAlta Pty Ltd., H1 2016 21
Pipeline by Bristol-Myers Squibb Company, H1 2016 22
Pipeline by Epigen Biosciences, Inc., H1 2016 23
Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 24
Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 25
Pipeline by RxBio, Inc., H1 2016 26
Pipeline by Sanofi, H1 2016 27
Dormant Projects, H1 2016 39
Dormant Projects (Contd..1), H1 2016 40
List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Mechanism of Actions, H1 2016 15
Number of Products by Stage and Mechanism of Actions, H1 2016 15
Number of Products by Routes of Administration, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 17
Number of Products by Molecule Types, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 19
